Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Titel:
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Auteur:
Schadendorf, Dirk Hauschild, Axel Santinami, Mario Atkinson, Victoria MandalĂ , Mario Chiarion-Sileni, Vanna Larkin, James Nyakas, Marta Dutriaux, Caroline Haydon, Andrew Robert, Caroline Mortier, Laurent Lesimple, Thierry Plummer, Ruth Schachter, Jacob Dasgupta, Kohinoor Manson, Stephanie Koruth, Roy Mookerjee, Bijoyesh Kefford, Richard Dummer, Reinhard Kirkwood, John M Long, Georgina V